TIMP-2在乳腺癌中的表达及临床意义

目的:探讨组织金属蛋白酶抑制剂-2（tissue inhibitors of metalloproteinase-2，TIMP-2）在乳腺正常组织、不典型增生、原位癌、浸润性癌组织中的表达水平，分析其与浸润性乳腺癌临床病理指标及乳腺癌生存情况之间的关系。方法:收集20例正常乳腺组织、28例不典型增生、40例导管内癌、80例浸润性乳腺癌标本，用免疫组化SP法检测各组TIMP-2的表达，分析其在浸润性乳腺癌不同临床病理指标分组中的表达差异；并通过120例乳腺癌患者的随访，分析其对乳腺癌生存状况的影响。结果:TIMP-2在乳腺正常组织（25.0%）、不典型增生组织（28.6%）、原位癌组织（60.0%）、浸润性癌组织（66.3%）中表达阳性率依次增高，在乳腺原位癌与不典型增生之间比较有统计学差异（P＜0.05）。浸润性乳腺癌TIMP-2的表达在部分组织学分级分组中比较有统计学差异（P＜0.05），在不同月经状态、年龄、肿块大小、临床分期、淋巴结转移数目、激素受体状态分组之间无统计学差异(均P＞0.05)。原位癌TIMP-2表达阳性组5年无病生存率高于表达阴性组，有统计学差异（P＜0.05）；浸润性乳腺癌TIMP-2表达阳性组5年无病生存率与表达阴性组无统计学差异（P＞0.05）。结论:TIMP-2参与了乳腺癌发生、发展的过程，在乳腺癌不同发展阶段具有不同预后价值。

Expression and clinical significance of TIMP -2 in breast cancer

Objective:To dectect the expression of tissue inhibitors of metalloproteinase-2(TIMP-2) in normal breast tissue,atypical hyperplasia,ductal carcinoma in situ(DCIS) and invasive carcinoma,and to analyze the the relationship of TIMP-2 and parameters and clinical outcome of human breast cancer.Methods:The expression levels of TIMP-2 protein in 20 cases of normal breast tissue,28 cases of atypical hyperplasia,40 cases of DCIS and 80 cases of invasive carcinoma were detected using SP immunohistochemical technique.All the 120 cases of breast carcinoma were followed-up.Results:The expression levels of TIMP-2 in normal breast tissue(25.0%),atypical hyperplasia(28.6%),DCIS(60.0%) and invasive breast cancer(66.3%) increased gradually.There was statistical difference between DCIS group and atypical hyperplasia group(P＜0.05).The difference of the expressions of TIMP-2 within some groups of different pathology grade had statistical significance(P＜0.05).The 5-year disease-free survival ratio of patients of DCIS in TIMP-2 positive expression group was significantly higher than that in the negative group(P＜0.05).While the 5-year disease-free survival ratio of patients of the invasive carcinoma had no statistical significance between the positive and the negative group(P＞0.05).Conclusion:The TIMP-2 protein may be related to the occurrence and development process of breast cancer,and there were different prognostic values in different development phases of breast cancer.